EXPLAINERDEVELOPING Down 11.4% 中文

PacBio's cash runway meets a moving breakeven date

By · AI-assisted, human-reviewed and edited · · 8 sources · Fact-checked · 9 min read

Developing story · Last updated

Can PacBio fund itself to breakeven?

It isn't settled. At the last four quarters' average burn of $35.8 million, the $199.4 million PacBio had at Sep 30 would last into early 2028, the year it targets for breakeven, and the full $100 million stock program would add about two to three quarters (our calculation, not a forecast). PacBio expects burn to fall meaningfully in 2027; it has moved its breakeven date twice before.

What it means

What changed
PacBio can now sell up to $100 million of new shares; fully sold at the Nov 11 close, that adds 15.3% to its share count.
What hasn't changed
Its 2028 breakeven goal and year-end cash guide of $175–185 million stand, per the Nov 4 call.
Next · Feb 2027 (date not announced)
Fourth-quarter results: year-end cash against the $175–185 million guide, and 2027 guidance.

Confirmed

  • On Nov 10 PacBio signed an agreement to sell up to $100 million of new shares over time at market prices through Allen & Co., which earns up to 3% (SEC 8-K and prospectus).
  • It had $199.4 million of cash and investments at Sep 30 and $641 million of convertible notes due in 2029 and 2030 (Q3 10-Q).
  • It expects cash-flow breakeven in 2028 and about $175–185 million of cash at the end of 2026, and narrowed its 2026 revenue range to $155–160 million (Nov 4 call).

Not known

  • How many shares PacBio will sell, when and at what prices. Neither it nor the agent has to sell any amount.
  • Why the program came six days after the call. The prospectus names only research, working capital and general corporate purposes.
  • Who the next chief financial officer will be, and how PacBio will meet the $200 million due in August 2029.
Move
▼ 11.4%
Price
$2.36 → $2.09
Value lost
~$84M
Cash, Sep 30
$199.4M
Average quarterly burn
$35.8M
Convertible notes
$641M

Prices: Yahoo Finance and CNBC historical close, Nov 11, 2026 · Company data: 10-Q, Sep 30, 2026 · What these numbers mean

Closing prices on Monday, Nov 9 (before the program was announced) and Wednesday, Nov 11, 2026 (Yahoo Finance and CNBC). The stock fell 5.1% on Nov 10 and 6.7% on Nov 11.

Snapshot at the Nov 11, 2026 close

Enterprise value
$1.1B
Price/sales
4.1×
P/E
n/m
Revenue growth
+4%
Net debt
$444M

Our calculation from the company's filings (latest: 10-Q for the quarter to Sep 30, 2026, filed Nov 5, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Sep 30, 2026. Price $2.09 (Yahoo Finance and CNBC historical close); 312.9 million shares (common shares on the cover page of the 10-Q filed Nov 5, 2026). n/m = not meaningful (e.g. negative earnings).

PacBio, which makes long-read DNA sequencers, said on Nov 10 that it may sell up to $100 million of new shares over time. The stock fell 11.4% over two days, to $2.09. The program came six days after its third-quarter call, where it kept its cash guidance and its 2028 breakeven target, and it puts a plain question: can the company reach breakeven before it needs more money?

What PacBio announced

An at-the-market program lets a company sell shares into the market a little at a time, at whatever the price is, through a broker acting as its agent. There is no fixed offering price or fixed discount, and no warrants; sales may be made in the market or in negotiated trades. PacBio’s agent is Allen & Co., which earns up to 3% of what it sells (8-K, prospectus).

  • Size: up to $100 million. At the Nov 9 close of $2.36 that is about 42.4 million shares, 13.6% more than the 312.2 million outstanding at Sep 30; at the Nov 11 close of $2.09 it would be about 47.8 million, 15.3% more (our calculation).
  • Use: research and development, working capital and general corporate purposes, per the prospectus.
  • No obligation: PacBio sells only if and when it chooses, and the agent isn’t required to sell any amount.

The timing is the tension. On Nov 4 PacBio narrowed its 2026 revenue range to $155–160 million, from $155–165 million, and kept its year-end cash guide of about $175–185 million and its 2028 breakeven goal. Six days later it set up the program. The company hasn’t said why then; its quarterly report says it expects “to require additional capital resources to execute our strategic initiatives” (10-Q).

How long the cash lasts

PacBio had $199.4 million of cash and investments at Sep 30, down from $279.5 million at the end of 2025, even after $48.1 million, net, from selling its short-read sequencing technology to Illumina in January. It says that is enough to fund its plans for more than 12 months. Over the last four quarters, free cash flow averaged −$35.8 million a quarter, ranging from −$19.9 million (Q4 2025) to −$47.7 million (Q1 2026); four quarters is a short record, and the asset-sale money isn’t in those figures.

PacBio's cash and investments, actual and at past burn rates ($M)

At its average burn of the last four quarters, PacBio's $199.4 million would run out in the first quarter of 2028; with the full stock program, in the fourth quarter of 2028. PacBio targets breakeven in 2028.

ActualAt the 4-quarter average burnAt the 2-quarter average burn4-quarter burn, with the program2-quarter burn, with the program

PacBio's breakeven target: 2028PacBio's breakeven target: 2028−$100$0$100$200$300Q3 2025: $298.7MQ4 2025: $279.5MQ1 2026: $276MQ2 2026: $236.9MQ3 2026: $199.4M$200M notes due$200M notes dueQ3 20252027202820292030PacBio's breakeven target: 2028PacBio's breakeven target: 2028−$100$0$100$200$300Q3 2025: $298.7MQ4 2025: $279.5MQ1 2026: $276MQ2 2026: $236.9MQ3 2026: $199.4M$200M notes due$200M notes dueQ3 20252027202820292030

Cash, cash equivalents and investments at quarter-end, $ millions

Our arithmetic at past burn rates, not a forecast. The dotted marker is the $200 million of convertible notes due Aug 15, 2029. The program lines assume the full $100 million is raised in the fourth quarter of 2026, less the 3% maximum commission: $97 million before estimated offering expenses of about $0.5 million and agent reimbursements. PacBio's own guide is $175–185 million at the end of 2026, then burn that steps down "meaningfully" in 2027; it gives no 2027 figure.

Actual: PacBio 10-Qs and 10-K (cash, cash equivalents and investments; the Q1 2026 balance includes $48.1M, net, from the short-read asset sale). Projections, our calculation: the Sep 30, 2026 balance less average quarterly free cash flow (operating cash flow minus capital spending) of $35.8M (Q4 2025–Q3 2026; quarters ranged from −$19.9M to −$47.7M) or $37.9M (Q2–Q3 2026 only: −$37.1M and −$38.6M). Lines stop at the first quarter-end below zero.
Show the data table
Quarter-end Actual 4-quarter burn 2-quarter burn 4-quarter burn + program 2-quarter burn + program
Q3 2025 298.7
Q4 2025 279.5
Q1 2026 276.0
Q2 2026 236.9
Q3 2026 199.4 199.4 199.4 199.4 199.4
Q4 2026 163.6 161.6 260.6 258.6
Q1 2027 127.7 123.7 224.7 220.7
Q2 2027 91.9 85.8 188.9 182.8
Q3 2027 56.0 48.0 153.0 145.0
Q4 2027 20.2 10.1 117.2 107.1
Q1 2028 below zero below zero 81.3 69.2
Q2 2028 45.5 31.4
Q3 2028 9.6 below zero
Q4 2028 below zero

In quarters, $199.4 million lasts about 5.6 at the four-quarter average burn and 5.3 at the two-quarter average; with the full program, about 8.3 and 7.8 (our calculation).

The company expects better than that. Its year-end cash guide implies a fall of about $14–24 million in the fourth quarter, against $37.6 million of operating cash outflow in the third, which it put partly down to the timing of payables and receivables. It expects cash burn “to step down meaningfully in 2027” on $30–40 million of annual cost savings, half from job cuts and half from lower development spending as its next sequencer nears launch (Nov 4 call).

The $641 million of convertible notes

PacBio owes $641 million of convertible notes and reported no other borrowings. Interest is about $9 million a year (our calculation).

Notes Principal Interest Converts at about Due
2029 $200.0M 1.50% $4.89 a share Aug 15, 2029
2030 $441.0M 1.375% $21.50 a share Dec 15, 2030

At $2.09, both conversion prices are far above the share price, so turning the notes into shares wouldn’t pay for holders at today’s price; unless that changes, they are debt to be repaid, exchanged or refinanced. The $200 million due in 2029 is about the size of all of PacBio’s Sep 30 cash. Asked on Nov 4 whether its breakeven plan covers that payment, CEO Mark Van Oene said there was “no immediate burning need” to address the maturities, citing “great relationships with both of the holders of the convertibles”, which had shown “some flexibility” before. PacBio has exchanged its notes twice: in 2023 for the 2030 notes, and in 2024, when SoftBank’s SB Northstar swapped $459 million of 2028 notes for the 2029 notes, 20.5 million shares and $50 million of cash (10-Q).

The record against its own targets

In 2022 PacBio aimed for over $500 million of revenue, gross margins of 55–60% or more and positive cash flow, all in 2026 (investor day transcript); it now expects $155–160 million of 2026 revenue and breakeven in 2028, after moving the date to “exiting 2027” in February 2025 and to 2028 in August 2026 (Q2 call). Along the way it cut about a quarter of its staff in 2024 and about 40 more jobs this year.

PacBio's 2026 revenue: the 2022 target against the current guide ($M)

In 2022 PacBio aimed for over $500 million of revenue in 2026; it now expects $155–160 million, about what it made in 2025.

Current 2026 guideTargets and actuals

2022 investor-day target for 2026 (over $500M)2022 investor-day target for 2026 (over $500M): $500M (Targets and actuals)$500MFirst 2026 guide, midpoint ($165–180M)First 2026 guide, midpoint ($165–180M): $172.5M (Targets and actuals)$172.5M2026 guide now, midpoint ($155–160M)2026 guide now, midpoint ($155–160M): $157.5M (Current 2026 guide)$157.5M2025 actual2025 actual: $160M (Targets and actuals)$160M2022 investor-day target for 2026 (over $500M)2022 investor-day target for 2026 (over $500M): $500M (Targets and actuals)$500MFirst 2026 guide, midpoint ($165–180M)First 2026 guide, midpoint ($165–180M): $172.5M (Targets and actuals)$172.5M2026 guide now, midpoint ($155–160M)2026 guide now, midpoint ($155–160M): $157.5M (Current 2026 guide)$157.5M2025 actual2025 actual: $160M (Targets and actuals)$160M
PacBio 2022 investor day transcript (Stock Analysis); first 2026 guidance from PacBio's Q4 2025 prepared remarks, Feb 12, 2026; current guide from the Nov 4, 2026 call; 2025 revenue from the 2025 10-K. Midpoints are our calculation.
Show the data table
Measure Revenue ($M)
2022 investor-day target for 2026 (over $500M) 500
First 2026 guide, midpoint ($165–180M) 172.5
2026 guide now, midpoint ($155–160M) 157.5
2025 actual 160.0

Revenue guidance was cut during the year in each of 2024, 2025 and 2026. For 2024, PacBio first guided to $230–250 million (Q4 2023 remarks); revenue came in at $154.0 million. For 2026 it first guided to $165–180 million in February (Q4 2025 remarks). Chief financial officer Jim Gibson stepped down with the third-quarter results; Van Oene is interim CFO while PacBio searches for a successor (Q3 release).

The business behind the burn

Revenue has sat near $40 million a quarter while costs have come down. Third-quarter revenue was $40.6 million, up 6% from a year earlier: consumables $20.8 million, instruments $13.2 million and service $6.6 million.

  • Cheaper genomes, less per machine: PacBio quotes a US list price of $345 per 20x HiFi human genome with its newest chemistry, SPRQ-Nx. Consumables revenue per Revio system ran at about $204,000 a year in the quarter, against about $236,000 a year earlier. The company expects that figure to return to $225,000–250,000 in 2027 as lower prices bring more samples.
  • Margins: non-GAAP gross margin fell to 36%, from 42%, which PacBio blamed on memory-chip costs and a manufacturing change for its Vega benchtop machine.
  • Costs: non-GAAP operating expenses, which include stock pay, are guided at $203–207 million for 2026, down from $354.8 million in 2023. Staff fell to 445 at Sep 30.
  • The gap: in the third quarter, non-GAAP gross profit of $14.6 million covered about a third of the $47.0 million of non-GAAP operating expenses (our calculation).
  • Customers: in the Americas, instrument revenue fell about 24% as “NIH and broader academic funding uncertainty” weighed on purchases, while consumables grew about 9%. Clinical labs are growing; GeneDx plans to add long-read genomes. In China, Berry Genomics took 10 Revios for a national birth-defects program.

The trade-off is in the chemistry: a lower price per genome helps win larger clinical and population projects, but each machine has to run more samples to bring in the same revenue.

What has to go right

By PacBio’s own plan, several things have to happen together. These are the company’s expectations, not ours.

  • Burn falls: from $37.6 million of operating cash outflow in the third quarter to the $14–24 million fall in cash its year-end guide implies, then “meaningfully” lower in 2027.
  • Costs keep falling: $30–40 million a year of savings from the restructuring and the end of heavy development spending.
  • Use per machine rises: consumables per Revio back to $225,000–250,000 in 2027 as SPRQ-Nx reorders arrive.
  • Margins recover from 36% as memory costs and the Vega transition ease.
  • The new sequencer launches by the end of 2027, for the larger projects a single Revio can’t handle.
  • The 2029 notes are met: repaid, exchanged or refinanced, with or without help from the stock program.

What to watch

The fourth-quarter results, expected in February 2027, will show year-end cash against the $175–185 million guide, any shares sold under the program and 2027 guidance. After that come the high-throughput sequencer (by the end of 2027), the 2028 breakeven target and the $200 million of notes due on Aug 15, 2029.

What to watch next

Feb 2027 (date not announced)
Fourth-quarter results: year-end cash against the $175–185 million guide, 2027 guidance, and any shares sold under the program.
By the end of 2027
PacBio's high-throughput long-read sequencer; the CEO said on Nov 4 it is on track for a commercial launch by the end of 2027.
2028
PacBio's target for cash-flow breakeven, moved from 2026 and then from "exiting 2027".
Aug 15, 2029
$200 million of 1.50% convertible notes mature; they convert at about $4.89 a share.

Quick questions

What is an at-the-market program?

A way to sell new shares a little at a time on the stock exchange at the going price, through a broker acting as agent, instead of in one priced deal. PacBio's covers up to $100 million, with Allen & Co. as agent.

Does PacBio have to sell all $100 million of stock?

No. The prospectus says sales are made only if and when PacBio chooses, and the agent isn't required to sell any specific amount.

How much debt does PacBio have?

$641 million of convertible notes: $200 million at 1.50% due August 2029, convertible at about $4.89 a share, and $441 million at 1.375% due December 2030, at about $21.50. It reported no other borrowings.

When does PacBio expect to break even?

In 2028, on a cash-flow basis, as it said on Nov 4. At its 2022 investor day it targeted positive cash flow in 2026; in February 2025 it said "exiting 2027".

About PacBio: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.